The Efficacy and Safety/Tolerability of Subcutaneous Tildrakizumab (SCH 900222/MK-3222), in Moderate-to-Severe Chronic Plaque Psoriasis Primary Efficacy Objective: To assess the efficacy of tildrakizumab (SCH-900222/MK-3222) (hereafter referred to as MK-3222) compared to placebo in the treatment of moderate-to-severe chronic plaque ps...

• Country None
• organs None
• Specialty None

Comparison of Pediatric Formulation (liquid) to Adult Formulation (tablets) To evaluate the comparative bioavailability between: • MK-5348 (vorapaxar) 0.2085 mg/mL oral suspension from Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., USA; and • MK-5348 (Zontiv...

• Country None
• organs None
• Specialty None

Vaginal ring dysmenorrhea feasibility trial To identify at least one dose of progestin/estrogen amongst the 4 active doses being tested, administered as a vaginal ring, that shows clinically relevant treatment efficacy in relief of primary dysm...

• Country None
• organs None
• Specialty None

Fosaprepitant PK/PD CINV in Pediatric Cancer Patients To determine the appropriate dosing regimen of fosaprepitant for the prevention of CINV in pediatric patients birth to 17 years of age, by assessing the pharmacokinetic and pharmacodynamic parameters,...

• Country None
• organs None
• Specialty None

A clinical study in patients with complicated intra-abdominal infections (infections situated within the cavity of the abdomen) conducted to assess safety, tolerability and efficacy of the study drug (MK-7655) administered together with Imipenem/Cilastatin (an antibiotic) in comparison with Imipenem/Cilastatin administered alone 1. To evaluate the efficacy of two doses of MK-7655 + imipenem/cilastatin (250 mg and 125 mg), as compared with imipenem/cilastatin alone, with respect to the clinical response assessment profile in t...

• Country None
• organs None
• Specialty None

A study to evaluate the safety and efficacy of the addition of a new drug (MK-3102) compared with placebo in patients with Type 2 Diabetes. Estudio para evaluar la seguridad y eficacia de la adición de un nuevo fármaco (MK-3102) comparado con placebo en pacientes con Diabetes Mellitus de tipo 2 (1) After 24 weeks, to assess the effect of treatment with MK-3102 compared with placebo on A1C. (2) To assess the safety and tolerability of MK-3102. (1) Al cabo de 24 semanas, evaluar el efe...

• Country None
• organs None
• Specialty None

PhII Trial of Pembrolizumab in Advanced Solid Tumors Ensayo clínico de Fase II con pembrolizumab en pacientes con tumores sólidos avanzados Objective 1: To evaluate the ORR to pembrolizumab, based on RECIST 1.1 as assessed by independent central radiologic review, in biomarker-unselected subjects with any one of multiple types of advance...

• Country None
• organs None
• Specialty None

A randomized study to assess efficacy and safety of Anaceptrapib when added to ongoing lipid-lowering therapy 1. Evaluate the efficacy of adding anacetrapib 100 mg for 52 weeks relative to placebo on plasma concentrations of LDL-C. 2. Evaluate the safety and tolerability of 52 weeks of treatment with anacetr...

• Country None
• organs None
• Specialty None

A Phase III, Randomized, Placebo-Controlled, Clinical Trial to Study the Safety and Immunogenicity of V920 Ebola Vaccine in Healthy Adults Ensayo clínico de fase III, aleatorizado y controlado con placebo para evaluar la seguridad y la capacidad inmunógena de la vacuna contra el virus del Ébola V920) en adultos sanos 1-To determine whether vaccination with V920 from three separate consistency lots results in equivalent immunogenicity. 2- To determine the safety and tolerability of V920 from three Consistency Lot g...

• Country None
• organs None
• Specialty None

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of MK-4305 in Patients with Primary Insomnia- Study B All Main/Primary objectives are MK-4305 high dose compared to placebo, as measured by change from baseline: Maintenance- 1. Mean subjective total sleep time (sTSTm) at Month 1 2. Wakefulness after p...

• Country None
• organs None
• Specialty None